title: Potential role of statins in the intracerebral hemorrhage and subarachnoid hemorrhage.
abstract: Statins are used in primary and secondary prevention of cardiovascular episodes. Most of recent studies regard ischemic stroke. There are more emerging results of studies suggesting usefulness of these drugs in the other types of stroke e.g. intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Searching for new methods of treatment is important, because both ICH and SAH lead to poor prognosis and severe psychomotor disability. The unquestionable role of inflammatory factors in the pathogenesis of these disorders justifies considering statin treatment. Previous results are contradictory, thus in present study we review results of studies and try to explain the potential pathomechanism of statin use in hemorrhagic strokes.
authors.affiliation: Department of Neurology, Pomeranian Medical University, Szczecin, Poland. Electronic address: dkotlega@poczta.onet.pl.
authors.forename: Dariusz
authors.initials: D
authors.lastname: Kotlęga
authors.affiliation: Department of Neurology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Gołąb-Janowska
authors.affiliation: Department of Neurology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Masztalewicz
authors.affiliation: Department of Gynaecology and Urogynaecology, Pomeranian Medical University, Police, Poland.
authors.forename: Sylwester
authors.initials: S
authors.lastname: Ciećwież
authors.affiliation: Department of Neurology, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Przemysław
authors.initials: P
authors.lastname: Nowacki
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001929:Brain Edema / Q000209:etiology / Q000503:physiopathology; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation; D007501:Iron / Q000378:metabolism; D015201:Meta-Analysis as Topic; D017628:Microglia / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects; D018579:Patient Selection; D017382:Reactive Oxygen Species / Q000378:metabolism; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013917:Thrombin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species; D007501:Iron; D013917:Thrombin
keywords: Inflammation; Intracerebral hemorrhage; Statins; Subarachnoid hemorrhage